Brought to you by 
BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics
Sep 2016
Executive Summary
Boehringer Ingelheim Pharmaceuticals Inc. entered into a collaboration with ViraTherapeutics GMBH to develop a next generation oncolytic virus platform based on ViraTherapeutics' lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) currently in preclinical development for solid cancers.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes M&A Option
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice